Literature DB >> 20530684

Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C.

Rozita Bagheri-Yarmand1, Angela Nanos-Webb, Anna Biernacka, Tuyen Bui, Khandan Keyomarsi.   

Abstract

The cyclin E-cyclin-dependent kinase 2 (CDK2) complex accelerates entry into the S phase of the cell cycle and promotes polyploidy, which may contribute to genomic instability in cancer cells. The effect of low molecular weight isoforms of cyclin E (LMW-E) overexpression on mitotic progression and its link to genomic instability were the focus of this study. Here, we show that full-length cyclin E (EL) and LMW-E overexpression impairs the G(2)-M transition differently by targeting dual-specificity phosphatase Cdc25C activity. We identify Cdc25C as an interaction partner and substrate for cyclin E/CDK2 kinase. Specifically, the cyclin E/CDK2 complex phosphorylates Cdc25C on Ser(214), leading to its premature activation, which coincides with higher cyclin B/CDK1 and Polo-like kinase 1 (PLK1) activities in an S-phase-enriched population that result in faster mitotic entry. Whereas EL overexpression leads to hyperactivation of Cdc25C, cyclin B/CDK1, and PLK1 in a G(2)-M-enriched population, LMW-E overexpression causes premature inactivation of Cdc25C and PLK1, leading to faster mitotic exit. In addition, LMW-E-overexpressing cells showed a reduction in the mitotic index in the presence of a spindle poison and faster degradation of cyclin B, suggesting an increased rate of mitotic slippage and adaptation to the spindle checkpoint. Lastly, downregulation of Cdc25C inhibits LMW-E-mediated chromosome missegregation, anaphase bridges, and centrosome amplification. These results suggest that the high levels of LMW-E isoforms found in breast cancer may contribute to cellular transformation and genomic instability by impairing mitotic progression involving Cdc25C.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20530684      PMCID: PMC2946214          DOI: 10.1158/0008-5472.CAN-09-4095

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle.

Authors:  S V Ekholm; S I Reed
Journal:  Curr Opin Cell Biol       Date:  2000-12       Impact factor: 8.382

Review 2.  Mitotic kinases as regulators of cell division and its checkpoints.

Authors:  E A Nigg
Journal:  Nat Rev Mol Cell Biol       Date:  2001-01       Impact factor: 94.444

Review 3.  Centrosome aberrations: cause or consequence of cancer progression?

Authors:  Erich A Nigg
Journal:  Nat Rev Cancer       Date:  2002-11       Impact factor: 60.716

4.  Merotelic kinetochore orientation occurs frequently during early mitosis in mammalian tissue cells and error correction is achieved by two different mechanisms.

Authors:  Daniela Cimini; Ben Moree; Julie C Canman; E D Salmon
Journal:  J Cell Sci       Date:  2003-09-02       Impact factor: 5.285

5.  Cyclin E and survival in patients with breast cancer.

Authors:  Khandan Keyomarsi; Susan L Tucker; Thomas A Buchholz; Matthew Callister; Ye Ding; Gabriel N Hortobagyi; Isabelle Bedrosian; Christopher Knickerbocker; Wendy Toyofuku; Michael Lowe; Thaddeus W Herliczek; Sarah S Bacus
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

6.  Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms.

Authors:  D C Porter; N Zhang; C Danes; M J McGahren; R M Harwell; S Faruki; K Keyomarsi
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

7.  Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells.

Authors:  R Bagheri-Yarmand; M Mandal; A H Taludker; R A Wang; R K Vadlamudi; H J Kung; R Kumar
Journal:  J Biol Chem       Date:  2001-05-29       Impact factor: 5.157

8.  Dual phosphorylation controls Cdc25 phosphatases and mitotic entry.

Authors:  Dmitry V Bulavin; Yuichiro Higashimoto; Zoya N Demidenko; Sarah Meek; Paul Graves; Crissy Phillips; Hui Zhao; Sally A Moody; Ettore Appella; Helen Piwnica-Worms; Albert J Fornace
Journal:  Nat Cell Biol       Date:  2003-06       Impact factor: 28.824

9.  Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.

Authors:  Said Akli; Ping-Ju Zheng; Asha S Multani; Hannah F Wingate; Sen Pathak; Ning Zhang; Susan L Tucker; Sandy Chang; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

10.  Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells.

Authors:  Catherine Lindon; Jonathon Pines
Journal:  J Cell Biol       Date:  2004-01-19       Impact factor: 10.539

View more
  16 in total

Review 1.  Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies.

Authors:  Joseph A Caruso; Mylinh T Duong; Jason P W Carey; Kelly K Hunt; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2018-09-07       Impact factor: 12.701

2.  CDKN2A, CDK1, and CCNE1 overexpression in sebaceous gland carcinoma of eyelid.

Authors:  Tatsuya Yunoki; Tetsushi Hirano; Yoshiaki Tabuchi; Yukihiro Furusawa; Misako Torigoe; Takahiko Nakajima; Johji Imura; Atsushi Hayashi
Journal:  Int Ophthalmol       Date:  2019-09-30       Impact factor: 2.031

3.  Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E.

Authors:  Said Akli; Carolyn S Van Pelt; Tuyen Bui; Laurent Meijer; Khandan Keyomarsi
Journal:  Cancer Res       Date:  2011-03-08       Impact factor: 12.701

Review 4.  In the wrong place at the wrong time: does cyclin mislocalization drive oncogenic transformation?

Authors:  Jonathan D Moore
Journal:  Nat Rev Cancer       Date:  2013-02-07       Impact factor: 60.716

5.  Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer.

Authors:  Cansu Karakas; Anna Biernacka; Tuyen Bui; Aysegul A Sahin; Min Yi; Said Akli; Jolie Schafer; Angela Alexander; Opoku Adjapong; Kelly K Hunt; Khandan Keyomarsi
Journal:  Am J Pathol       Date:  2016-05-13       Impact factor: 4.307

6.  Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.

Authors:  Xian Chen; Kwang-Huei Low; Angela Alexander; Yufeng Jiang; Cansu Karakas; Kenneth R Hess; Jason P W Carey; Tuyen N Bui; Smruthi Vijayaraghavan; Kurt W Evans; Min Yi; D Christian Ellis; Kwok-Leung Cheung; Ian O Ellis; Siqing Fu; Funda Meric-Bernstam; Kelly K Hunt; Khandan Keyomarsi
Journal:  Clin Cancer Res       Date:  2018-09-04       Impact factor: 12.531

7.  Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells.

Authors:  Olga V Leontieva; Felicia Lenzo; Zoya N Demidenko; Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2012-11-27       Impact factor: 4.534

Review 8.  A clinical overview of centrosome amplification in human cancers.

Authors:  Jason Yongsheng Chan
Journal:  Int J Biol Sci       Date:  2011-10-16       Impact factor: 6.580

9.  High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.

Authors:  M P H M Jansen; E A Reijm; A M Sieuwerts; K Ruigrok-Ritstier; M P Look; F G Rodríguez-González; A A J Heine; J W Martens; S Sleijfer; J A Foekens; E M J J Berns
Journal:  Breast Cancer Res Treat       Date:  2011-11-18       Impact factor: 4.872

10.  A PREVIOUSLY UNKNOWN UNIQUE CHALLENGE FOR INHIBITORS OF SYK ATP-BINDING SITE: ROLE OF SYK AS A CELL CYCLE CHECKPOINT REGULATOR.

Authors:  Fatih M Uckun; Hong Ma; Zahide Ozer; Patricia Goodman; Jian Zhang; Sanjive Qazi
Journal:  EBioMedicine       Date:  2014-11-01       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.